ArticleEULAR rheumatology open2025
Mortality rates in children, young people, and young adults with JIA: an observational study using the Clinical Practice Research Datalink (CPRD).
Article in EULAR rheumatology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Many rheumatological conditions have increased mortality rates; however, there is conflicting evidence regarding the impact of juvenile idiopathic arthritis (JIA) on mortality. This analysis aimed to calculate the all-cause mortality rate of patients with JIA, compared with (a) matched-control patients and (b) the general population mortality estimates. Methods: Using the UK General Practice data Clinical Practice Research Datalink, JIA cases starting <16 years old from England were included, matched 4-to-1 with non-JIA controls (birth year, gender, practice). Exposure started on first JIA-code date (matched-date for controls) or January 1, 2000, whichever was latest. Follow-up continued until December 31, 2018, or death, whichever was first. Cox-proportional hazards models compared mortality in JIA versus matched controls. JIA rates were stratified by systemic versus non-systemic JIA. Standardised mortality rates (SMRs) were generated for JIA versus general population estimates (calendar year, age, gender). Results: There were 4762 patients with JIA (30 deaths) and 13 957 matched controls (27 deaths); patient demographics were similar between cohorts. Mortality rate for JIA was 6.2/10 000 person years (95% CI: 4.3-8.9), and 1.9/10 000 person years (95% CI: 1.3-2.8) for matched controls; JIA patients had 3.3 times higher mortality (95% CI: 2.0-5.5). Patients with systemic JIA had 3.3 times higher mortality (95% CI: 1.6-6.9) versus those with non-systemic JIA. The SMR for JIA was 2.9 (95% CI: 2.1-4.2). Eighteen (60%) JIA deaths occurred before 2012. Conclusions: This analysis calculated mortality rates in young people with JIA in England. Death in young people with JIA is exceedingly rare. Higher rates were observed in patients with systemic JIA. Over half the deaths occurred prior to 2012 when biologic treatment, particularly for systemic JIA, was limited.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.